Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 22;32(1):37.
doi: 10.1186/s44348-024-00036-z.

Contemporary diagnosis and treatment of valvular heart disease in Korea: a nationwide hospital-based registry study

Hyung Yoon Kim #  1 , Hee Jeong Lee #  2 , In-Cheol Kim  2 , Jung-Woo Son  3 , Jun-Bean Park  4 , Sahmin Lee  5 , Eun Kyoung Kim  6 , Seong-Mi Park  7 , Woo-Baek Chung  8 , Jung Sun Cho  9 , Jin-Sun Park  10 , Jeong-Sook Seo  11 , Sun Hwa Lee  12 , Byung Joo Sun  5 , Chi Young Shim  13 , Hyungseop Kim  2 , Kye Hun Kim  14 , Duk-Hyun Kang  5 , Jong-Won Ha  15 ; Korean Valve Survey Registry Investigators
Collaborators, Affiliations

Contemporary diagnosis and treatment of valvular heart disease in Korea: a nationwide hospital-based registry study

Hyung Yoon Kim et al. J Cardiovasc Imaging. .

Abstract

Background: This study was designed to determine the current status of diagnosis and treatment of valvular heart disease (VHD) in Korea.

Methods: A nationwide registry study was conducted in 45 hospitals in Korea involving adult patients with at least moderate VHD as determined by echocardiography carried out between September and October of 2019. Of a total of 4,094 patients with at least moderate VHD, 1,482 had severe VHD (age, 71.3 ± 13.5 years; 49.1% male). Echocardiographic data used for the diagnosis of each case of VHD were analyzed. Experts from each center determined the diagnosis and treatment strategy for VHD based on current guidelines and institutional policy. The clinical outcome was in-hospital mortality.

Results: Each valve underwent surgical or transcatheter intervention in 19.3% cases of severe mitral stenosis, 31.4% cases of severe primary mitral regurgitation (MR), 7.5% cases of severe secondary MR, 43.7% cases of severe aortic stenosis, 27.5% cases of severe aortic regurgitation, and 7.2% cases of severe tricuspid regurgitation. The overall in-hospital mortality rate for patients with severe VHD was 5.4%, and for secondary severe MR and severe tricuspid regurgitation, the rates were 9.0% and 7.5%, respectively, indicating a poor prognosis. In-hospital mortality occurred in 73 of the 1,244 patients (5.9%) who received conservative treatment and in 18 of the 455 patients (4.0%) who received a surgical or transcatheter intervention, which was significantly lower in the intervention group (P = 0.037).

Conclusions: This study provides important information about the current status of VHD diagnosis and treatment through a nationwide registry in Korea and helps to define future changes.

Keywords: Diagnosis; Heart valve diseases; Korea; Outcome; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study protocol was approved by the Institutional Review Board of Chonnam National University Hospital (No. CNUH-2021–203) and the participating centers, each of which waived the requirement for written informed consent because of the study’s retrospective nature and the anonymized approach to data analysis. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Etiology of each severe valvular heart disease in Korea. Pie charts showing the distribution of the etiology of (A) mitral stenosis, (B) primary mitral regurgitation, (C) secondary mitral regurgitation, (D) aortic stenosis, (E) aortic regurgitation, and (F) tricuspid regurgitation
Fig. 2
Fig. 2
Approaches based on the multimodal imaging for each valvular heart disease. MS, mitral stenosis; MR, mitral regurgitation; AS, aortic stenosis; AR, aortic regurgitation; TR, tricuspid regurgitation; D, dimensional; TEE, transesophageal echocardiography; CT, computed tomography; CMR, cardiac magnetic resonance
See this image and copyright information in PMC

References

    1. Coffey S, Roberts-Thomson R, Brown A, Carapetis J, Chen M, Enriquez-Sarano M, et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18:853–64. - PubMed
    1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72-227. - PubMed
    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632. - PubMed
    1. Lee SH, Yoon SJ, Sun BJ, Kim HM, Kim HY, Lee S, et al. 2023 Korean Society of Echocardiography position paper for the diagnosis and management of valvular heart disease, part I: aortic valve disease. J Cardiovasc Imaging. 2024;32:11. - PMC - PubMed
    1. Shim CY, Kim EK, Cho DH, Park JB, Seo JS, Son JW, et al. 2023 Korean Society of Echocardiography position paper for the diagnosis and management of valvular heart disease, part II: mitral and tricuspid valve disease. J Cardiovasc Imaging. 2024;32:10. - PMC - PubMed

LinkOut - more resources